COMPASS Pathways plc (CMPS)

COMPASS Pathways plc (CMPS) Healthcare & Pipeline Overview

COMPASS Pathways plc is a London-headquartered mental healthcare company pioneering investigational psilocybin therapy, COMP360, for treatment-resistant depression and post-traumatic stress disorder. The firm is advancing its lead product through crucial clinical trial phases, positioning itself at the forefront of psychedelic-assisted therapy development within the medical care facilities sector.

What Is the Investment Thesis for CMPS?

COMPASS Pathways plc (CMPS) presents a unique investment profile centered on its pioneering work in psychedelic-assisted therapy, specifically COMP360 for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company's valuation, evidenced by its $1.24B market capitalization, reflects investor interest in its lead asset's potential. The progression of COMP360 through Phase IIb trials for TRD and ongoing Phase II trials for PTSD represents significant de-risking milestones. Successful completion of these trials and subsequent regulatory approvals could unlock substantial market opportunities, given the high unmet needs in these conditions. The high beta of 2.51 indicates significant volatility, characteristic of early-stage biopharmaceutical companies. Key growth catalysts include positive clinical trial readouts, regulatory designations (e.g., Breakthrough Therapy), and potential commercialization partnerships. The absence of a dividend underscores the company's focus on reinvesting capital into R&D. Risks include clinical trial failures, regulatory hurdles, and intense competition in the mental health space, alongside the unique challenges associated with developing controlled substances.

Based on FMP financials and quantitative analysis

CMPS Key Highlights

• Market capitalization of $1.24B reflects investor valuation of its investigational psilocybin therapy pipeline.
• High beta of 2.51 indicates significant stock price volatility, typical for a clinical-stage biopharmaceutical company.
• COMP360, the lead investigational psilocybin therapy, has advanced through Phase IIb clinical trials for treatment-resistant depression.
• The company is actively pursuing further clinical development with COMP360, currently in Phase II trials for post-traumatic stress disorder.
• COMPASS Pathways plc does not currently pay a dividend, signaling a strategy of reinvesting earnings into research and development to accelerate pipeline progression.

Who Are CMPS's Competitors?

CMPS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CMPS's Key Strengths?

• Advanced clinical pipeline with COMP360 in Phase IIb for TRD and Phase II for PTSD.
• Pioneering position in the emerging field of psychedelic-assisted therapy.
• Strong focus on conditions with high unmet medical needs.
• Experienced leadership team navigating complex regulatory environments.

What Are CMPS's Weaknesses?

• Reliance on a single lead product (COMP360) for near-term revenue potential.
• High R&D costs and no current revenue streams from product sales.
• Significant regulatory hurdles associated with controlled substances.
• High beta (2.51) indicates substantial stock price volatility.

What Could Drive CMPS Stock Higher?

• Positive clinical trial readouts for COMP360 in Phase II for post-traumatic stress disorder, expected to provide further validation of its therapeutic potential.
• Advancement of COMP360 into Phase III clinical trials for treatment-resistant depression, signaling progression towards potential regulatory submission.
• Potential for Breakthrough Therapy or other expedited regulatory designations for COMP360, which could accelerate its path to market approval.
• Formation of strategic partnerships or collaborations to support the commercialization and broader distribution of COMP360 upon approval.

What Are the Key Risks for CMPS?

• Financial-distress signal — its Altman Z-Score of 1.61 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events during ongoing Phase II trials for PTSD or future Phase III trials for TRD, which could halt development.
• Significant regulatory hurdles and delays associated with obtaining approval for a Schedule I controlled substance like psilocybin in various jurisdictions.
• Intense competition from other biopharmaceutical companies developing psychedelic-assisted therapies or novel mental health treatments.
• High cash burn rate typical of clinical-stage biopharmaceutical companies with no current revenue from product sales, necessitating future capital raises.
• Public perception and stigma associated with psychedelic compounds, which could impact patient adoption and market acceptance even after regulatory approval.

What Are the Growth Opportunities for CMPS?

• **Expansion into Treatment-Resistant Depression Market:** The global market for depression treatments is substantial, with treatment-resistant depression (TRD) representing a significant unmet need. COMPASS Pathways' COMP360 has completed Phase IIb trials for TRD, indicating a clear path towards potentially addressing this patient population. Successful Phase III trials and subsequent regulatory approval could position COMP360 as a breakthrough therapy, capturing a share of a market estimated to be worth billions. The timeline for this opportunity extends over the next 3-5 years, contingent on trial success and regulatory clearances, offering a significant competitive advantage as an early mover in a novel therapeutic class.
• **Development for Post-Traumatic Stress Disorder (PTSD):** COMPASS Pathways is actively pursuing the development of COMP360 for post-traumatic stress disorder (PTSD), with Phase II trials currently underway. The global PTSD treatment market is also substantial, with existing therapies often having limited efficacy or undesirable side effects. A successful outcome in PTSD trials could open up another multi-billion dollar market segment for COMP360. This represents a distinct growth opportunity over the medium term (3-7 years), diversifying the therapy's application and expanding the company's addressable patient population beyond depression.
• **Geographic Expansion and Market Penetration:** While COMPASS Pathways has a primary presence in the UK and US, the global burden of mental health disorders suggests significant opportunities for geographic expansion. Securing regulatory approvals in additional major markets, such as the European Union, Canada, and Australia, could substantially increase the potential patient base for COMP360. This growth driver involves navigating diverse regulatory landscapes and establishing international commercial partnerships, with a timeline extending beyond 5 years, but offering long-term revenue diversification and market leadership.
• **Pipeline Diversification and New Indications:** Beyond TRD and PTSD, the underlying mechanism of psilocybin therapy may have applications in other mental health conditions, such as anxiety disorders, obsessive-compulsive disorder, or substance use disorders. Investing in preclinical and early-stage clinical research for new indications could create a robust pipeline, reducing reliance on a single product. This long-term growth opportunity (5-10+ years) involves strategic R&D investment and could significantly expand the company's market reach and intellectual property portfolio, securing future revenue streams.
• **Strategic Partnerships and Commercialization:** As COMP360 progresses through late-stage clinical development, opportunities for strategic partnerships with larger pharmaceutical companies or specialized mental health providers will emerge. Such collaborations could provide critical funding, accelerate market access, and leverage established commercial infrastructure for distribution and patient support. These partnerships could significantly de-risk the commercialization phase and expand the reach of COMP360, representing a mid-to-long-term growth catalyst (2-7 years) that enhances market penetration and operational efficiency.

What Opportunities Does CMPS Have?

• Potential for breakthrough therapy designation and accelerated approval pathways.
• Expansion into additional mental health indications beyond TRD and PTSD.
• Global market expansion beyond current UK and US focus.
• Strategic partnerships for commercialization and distribution.

What Threats Does CMPS Face?

• Clinical trial failures or unexpected adverse events.
• Intense competition from other companies developing psychedelic therapies.
• Evolving and potentially restrictive regulatory landscape for controlled substances.
• Patent challenges or expiration impacting intellectual property protection.

What Are CMPS's Competitive Advantages?

• Proprietary formulation of psilocybin (COMP360) and associated intellectual property.
• Early mover advantage and established clinical trial progress in psychedelic-assisted therapy.
• Expertise in navigating complex regulatory pathways for controlled substances in mental health.
• Accumulated clinical data and safety profiles from ongoing and completed trials.

What Does CMPS Do?

COMPASS Pathways plc, established in 2020 and headquartered in London, UK, is a mental healthcare company dedicated to developing innovative treatments for mental health conditions. The company's primary focus is on its investigational psilocybin therapy, COMP360, which represents a significant advancement in the potential treatment landscape for severe mental health disorders. Initially operating as COMPASS Rx Limited, the company rebranded to COMPASS Pathways plc in August 2020, solidifying its identity and strategic direction in the burgeoning field of psychedelic medicine. The firm's research and development efforts are concentrated on addressing conditions with high unmet medical needs, particularly treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 has successfully completed Phase IIb clinical trials for TRD, demonstrating its progression through rigorous regulatory pathways. Concurrently, the therapy is undergoing Phase II trials for PTSD, indicating a broader application strategy for its lead candidate. With a primary operational presence spanning the United Kingdom and the United States, COMPASS Pathways aims to bring this novel therapeutic approach to patients globally. The company's commitment to scientific rigor and patient safety underpins its development process, as it navigates the complex regulatory and clinical landscape for psychedelic-assisted therapies. By focusing on a structured and evidence-based approach, COMPASS Pathways is positioning itself as a leader in transforming mental healthcare.

What Products and Services Does CMPS Offer?

• Develop investigational psilocybin therapy, COMP360, for mental health conditions.
• Conduct clinical trials, including Phase IIb for treatment-resistant depression and Phase II for post-traumatic stress disorder.
• Focus on novel treatments for conditions with high unmet medical needs.
• Operate as a mental healthcare company with a primary presence in the United Kingdom and the United States.
• Engage in research and development to advance psychedelic-assisted therapies.
• Aim to transform mental healthcare through evidence-based therapeutic approaches.

How Does CMPS Make Money?

• Research and development of novel psychedelic-assisted therapies.
• Seeking regulatory approval for investigational compounds like COMP360.
• Potential future revenue generation from commercialization of approved therapies, likely through licensing or direct sales.
• Focus on conditions with high unmet medical needs, such as treatment-resistant depression and PTSD.

What Industry Does CMPS Operate In?

COMPASS Pathways plc operates within the highly specialized and evolving Medical - Care Facilities industry, specifically targeting mental healthcare. The broader healthcare sector is experiencing a paradigm shift towards novel therapeutic modalities for mental health, driven by increasing prevalence rates of conditions like depression and PTSD and limitations of existing treatments. The market for psychedelic-assisted therapies, while nascent, is projected to grow significantly as regulatory frameworks evolve and clinical evidence accumulates. COMPASS Pathways is positioned as a frontrunner in this niche, focusing on psilocybin therapy. The competitive landscape includes other biopharmaceutical companies exploring psychedelic compounds, as well as established pharmaceutical firms with conventional antidepressant and anxiolytic portfolios. The company's success hinges on its ability to navigate complex clinical trials, secure regulatory approvals, and establish a scalable treatment delivery model within a highly regulated environment.

Who Are CMPS's Key Customers?

• Patients suffering from treatment-resistant depression (TRD).
• Patients diagnosed with post-traumatic stress disorder (PTSD).
• Healthcare providers and mental health clinics seeking innovative treatment options.
• Potentially, healthcare systems and insurers covering novel therapies.

Key Financial Metrics

Return on assets is -33.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.5%, the inverse of the P/E and a quick read on earnings relative to price.

COMPASS Pathways plc (CMPS) Valuation Context

Valued at $1.24B, CMPS is classified as a small-cap stock. Relative to its peer group, CMPS's quantitative score of 48/100 is below the peer average of 60/100.

Company Profile

COMPASS Pathways plc operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Kabir Kumar Nath. CMPS has traded publicly since 2020.

F-Score 2/9Financial Health

COMPASS Pathways plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.61 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project COMPASS Pathways plc revenue of about $2.3M for fiscal 2026, with EPS near $-0.73.

Net buyingInsider Activity

Over the past six months, COMPASS Pathways plc insiders filed 18 SEC Form 4 transactions — 4 sales and 14 purchases. On net that is roughly 1.1M shares acquired (about $5.7M) — insiders putting money in tends to read as conviction.

CMPS Financials

CMPS Latest News

CMPS Analyst Consensus

CMPS MoonshotScore

Latest COMPASS Pathways plc Analysis

What Investors Ask About COMPASS Pathways plc (CMPS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources